Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
Trial ID or NCT#
Status
Purpose
The purpose of this ÌÇÐÄ´«Ã½ study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.
Official Title
A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants.
Eligibility Criteria
- * Allogeneic stem cell transplant recipient* Recipient or donor CMV seropositive* Have transplant engraftment* Able to swallow tablets
- * CMV organ disease* HIV infection* Use of other anti-CMV therapy post-transplant
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Janice Brown
6507230822
View on